ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Kintor Pharmaceutical Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 66.64% and Operating profit at 7.74% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -154.34
2
Flat results in Jun 25
- RAW MATERIAL COST(Y) Grown by 21,481% (YoY)
- CASH AND EQV(HY) Lowest at HKD 58.38 MM
- DEBT-EQUITY RATIO (HY) Highest at 15.79 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 94.12%, its profits have risen by 86%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Kintor Pharmaceutical Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Kintor Pharmaceutical Ltd.
-100.0%
1.36
85.28%
Hang Seng Hong Kong
8.25%
0.41
19.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
66.64%
EBIT Growth (5y)
7.74%
EBIT to Interest (avg)
-154.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.17
EV to EBIT
-5.23
EV to EBITDA
-5.82
EV to Capital Employed
3.29
EV to Sales
180.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-62.93%
ROE (Latest)
-51.87%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
OPERATING CASH FLOW(Y)
Highest at HKD -466.5 MM
NET SALES(HY)
Higher at HKD 6.43 MM
NET PROFIT(HY)
Higher at HKD -89.44 MM
-5What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 21,481% (YoY
CASH AND EQV(HY)
Lowest at HKD 58.38 MM
DEBT-EQUITY RATIO
(HY)
Highest at 15.79 %
Here's what is working for Kintor Pharmaceutical Ltd.
Net Sales
Higher at HKD 6.43 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (HKD MM)
Net Profit
Higher at HKD -89.44 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (HKD MM)
Operating Cash Flow
Highest at HKD -466.5 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (HKD MM)
Depreciation
Highest at HKD 13.6 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 13.6 MM has Grown at 41.03%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Kintor Pharmaceutical Ltd.
Cash and Eqv
Lowest at HKD 58.38 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 15.79 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 21,481% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
